Bryn Mawr Capital Management LLC Buys 1,989 Shares of STERIS plc (NYSE:STE)

Bryn Mawr Capital Management LLC increased its holdings in shares of STERIS plc (NYSE:STE) by 236.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,829 shares of the medical equipment provider’s stock after purchasing an additional 1,989 shares during the period. Bryn Mawr Capital Management LLC’s holdings in STERIS were worth $582,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in STERIS by 0.7% in the third quarter. Geode Capital Management LLC now owns 2,303,625 shares of the medical equipment provider’s stock valued at $556,786,000 after acquiring an additional 17,007 shares during the period. Principal Financial Group Inc. raised its stake in shares of STERIS by 0.5% in the fourth quarter. Principal Financial Group Inc. now owns 1,119,643 shares of the medical equipment provider’s stock valued at $230,160,000 after buying an additional 5,419 shares during the period. Franklin Resources Inc. raised its stake in shares of STERIS by 171.2% in the third quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock valued at $191,370,000 after buying an additional 529,308 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of STERIS by 1.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 551,453 shares of the medical equipment provider’s stock valued at $133,749,000 after buying an additional 6,334 shares during the period. Finally, Swiss National Bank raised its stake in shares of STERIS by 0.3% in the third quarter. Swiss National Bank now owns 293,360 shares of the medical equipment provider’s stock valued at $71,152,000 after buying an additional 800 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Buying and Selling

In related news, SVP Cary L. Majors sold 1,682 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the transaction, the senior vice president now directly owns 11,372 shares in the company, valued at $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.14% of the stock is owned by company insiders.

STERIS Stock Performance

NYSE:STE opened at $220.43 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.40 and a current ratio of 2.13. STERIS plc has a 52-week low of $197.82 and a 52-week high of $248.24. The firm has a market cap of $21.66 billion, a price-to-earnings ratio of 46.80 and a beta of 0.84. The business’s fifty day moving average is $213.47 and its 200 day moving average is $223.64.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Research analysts predict that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 1.03%. The ex-dividend date of this dividend is Thursday, February 20th. STERIS’s payout ratio is 48.41%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. JMP Securities restated a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research note on Thursday, February 6th. Piper Sandler boosted their target price on STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Friday, November 8th. StockNews.com lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Finally, Stephens reiterated an “overweight” rating and set a $240.00 price objective on shares of STERIS in a research note on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $258.75.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.